MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1172/jci145666

Медицинская библиотека · The Journal of clinical investigation · 2022

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.

Rouanne Mathieu, Adam Julien, Radulescu Camélia, Letourneur Diane, Bredel Delphine, Mouraud Séverine, Goubet Anne-Gaëlle, Leduc Marion, Chen Noah, Tan Tuan Zea, Signolle Nicolas, Bigorgne Amélie, Dussiot Michael, Tselikas Lambros, Susini Sandrine, Danlos François-Xavier, Schneider Anna K, Chabanon Roman, Vacher Sophie, Bièche Ivan, Lebret Thierry, Allory Yves, Soria Jean-Charles, Arpaia Nicholas, Kroemer Guido, Kepp Oliver, Thiery Jean Paul, Zitvogel Laurence, Marabelle Aurélien

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumors, and samples from cohorts of patients with bladder cancer before and after BCG therapy, we demonstrate 2 distinct patterns of immune subversion upon BCG relapse. In the first pattern, intracellular BCG infection of cancer cells induced a posttranscriptional downregulation of HLA-I membrane expression via inhibition of autophagy flux. Patients with HLA-I-deficient cancer cells following BCG therapy had a myeloid immunosuppressive tumor microenvironment (TME) with epithelial-mesenchymal transition (EMT) characteristics and dismal outcomes. Conversely, patients with HLA-I-proficient cancer cells after BCG therapy presented with CD8+ T cell tumor infiltrates, upregulation of inflammatory cytokines, and immune checkpoint-inhibitory molecules. The latter patients had a very favorable outcome. We surmise that HLA-I expression in bladder cancers at relapse following BCG does not result from immunoediting but rather from an immune subversion process directly induced by BCG on cancer cells, which predicts a dismal prognosis. HLA-I scoring of cancer cells by IHC staining can be easily implemented by pathologists in routine practice to stratify future treatment strategies for patients with urothelial cancer.

Для цитирования: Rouanne Mathieu, Adam Julien, Radulescu Camélia, Letourneur Diane, Bredel Delphine, Mouraud Séverine, Goubet Anne-Gaëlle, Leduc Marion, Chen Noah, Tan Tuan Zea, Signolle Nicolas, Bigorgne Amélie, Dussiot Michael, Tselikas Lambros, Susini Sandrine, Danlos François-Xavier, Schneider Anna K, Chabanon Roman, Vacher Sophie, Bièche Ivan, Lebret Thierry, Allory Yves, Soria Jean-Charles, Arpaia Nicholas, Kroemer Guido, Kepp Oliver, Thiery Jean Paul, Zitvogel Laurence, Marabelle Aurélien. BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.. The Journal of clinical investigation. 2022. DOI: 10.1172/jci145666.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.